Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Surufatinib - a novel oral agent for neuroendocrine tumours.

Literature DB >> 33128026

Surufatinib - a novel oral agent for neuroendocrine tumours.

Anna Koumarianou^1,2, Gregory Kaltsas^3,4.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2021 PMID： 33128026 DOI： 10.1038/s41574-020-00439-0

Source DB: PubMed Journal: Nat Rev Endocrinol ISSN： 1759-5029 Impact factor: 43.330

× No keyword cloud information.

3 in total

1. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.

Authors: Christina Guo; Maxime Chénard-Poirier; Desamparados Roda; Maria de Miguel; Samuel J Harris; Irene Moreno Candilejo; Priya Sriskandarajah; Wen Xu; Mariana Scaranti; Anastasia Constantinidou; Jenny King; Mona Parmar; Alison J Turner; Suzanne Carreira; Ruth Riisnaes; Laura Finneran; Emma Hall; Yuji Ishikawa; Kiyohiko Nakai; Nina Tunariu; Bristi Basu; Martin Kaiser; Juanita Suzanne Lopez; Anna Minchom; Johann S de Bono; Udai Banerji
Journal: Lancet Oncol Date: 2020-10-28 Impact factor: 41.316

2. Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.

Authors: Jianming Xu; Jie Li; Chunmei Bai; Nong Xu; Zhiwei Zhou; Zhiping Li; Caicun Zhou; Ru Jia; Ming Lu; Yuejuan Cheng; Chenyu Mao; Wei Wang; Ke Cheng; Chunxia Su; Ye Hua; Chuan Qi; Jing Li; Wei Wang; Ke Li; Qiaoling Sun; Yongxin Ren; Weiguo Su
Journal: Clin Cancer Res Date: 2019-03-04 Impact factor: 12.531

3 in total

4 in total

Surufatinib - a novel oral agent for neuroendocrine tumours.

1. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.

2. Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.

1. Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms.

Review 2. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets.

Review 3. How VEGF-A and its splice variants affect breast cancer development - clinical implications.

Review 4. Immunotherapy: Reshape the Tumor Immune Microenvironment.